VIVORYON THERAPEUTICS N.V. |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.468 EUR | -0.43% |
|
-5.45% | -94.25% |
| Sales 2023 * | - | Sales 2024 * | - | Capitalization | 12.25M 13.06M |
|---|---|---|---|---|---|
| Net income 2023 * | -23M -24.52M | Net income 2024 * | -18M -19.19M | EV / Sales 2023 * | - |
| Net cash position 2023 * | 24.1M 25.69M | Net cash position 2024 * | 19.55M 20.84M | EV / Sales 2024 * | - |
| P/E ratio 2023 * |
-0.51
x | P/E ratio 2024 * |
-0.66
x | Employees | 15 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 66.82% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vivoryon Therapeutics N.V.
More press releases
| 1 day | -0.43% | ||
| 1 week | -5.45% | ||
| Current month | -13.33% | ||
| 1 month | -12.69% | ||
| 3 months | -93.85% | ||
| 6 months | -93.90% | ||
| Current year | -94.25% |
1 week
0.41
0.50
1 month
0.410.56
Current year
0.419.93
1 year
0.4119.56
3 years
0.4123.25
5 years
0.4123.25
10 years
0.4127.73
| Managers | Title | Age | Since |
|---|---|---|---|
Frank Weber
CEO | Chief Executive Officer | 64 | 11-12-31 |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Director/Board Member | 56 | 18-08-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 06-12-31 | |
| Director/Board Member | 54 | 06-12-31 | |
Anne Doering
DFI | Director of Finance/CFO | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.468 | -0.43% | 56 831 |
| 24-04-18 | 0.47 | +11.51% | 283,780 |
| 24-04-17 | 0.4215 | -10.98% | 374,611 |
| 24-04-16 | 0.4735 | -1.35% | 114,394 |
| 24-04-15 | 0.48 | -3.03% | 177,586 |
Real-time Euronext Amsterdam, April 19, 2024 at 05:57 am EDT
More quotes
Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease.
At the end of 2022, the group has a portfolio of a product in phase II clinical development (Varoglutamstat; PQ912) and 2 products in the preclinical development phase.
Calendar
2024-04-24
- Q4 2023 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.47
EUR
Average target price
41.57
EUR
Spread / Average Target
+8,743.97%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -94.25% | 13.06M | |
| -1.82% | 41.35B | |
| +42.44% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- VVY Stock
